Apr 23, 2020

FDA Approves Lanreotide for Neuroendocrine Tumors

The drug improves disease control in patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors.

Proceed to the page: http://linkis.com/UhvhE

Similar Articles Added Earlier

Latest Links Processed

0/120